Ovarian cancer treatment is evolving: more choices, more chances

n/

Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?

n/

Laparoscopic intra-operative ultrasound-guided bilateral salpingo-oophorectomy in a BRCA2 mutated patient

n/

A COMUNICAÇÃO INTERNA COMO RECURSO DE FORTALECIMENTO DA CULTURA ORGANIZACIONAL: UM ESTUDO DE CASO

With the efficiency of internal communication (IC) it is possible that managers can positively influence in the commitment of employees to the institution, internalizing the desired practices, which become part of work routines. When planning IC, managers should insert the cultural values of the organization, sending to employees, in many ways, messages about what the institution expects of them. With these prerogatives the present study aimed to identify, in the Unioeste / Campus Toledo IC, some vectors for transmission of cultural values. This research was characterized as a case study, of exploratory nature, and made use of questionnaires to all staff and occupants of Unioeste leadership positions. It was observed that there are some flaws in the process of IC which compromise the actions and achievement of institutional objectives, and lead to lack of involvement and commitment of those involved. Also it was found that the respondents believe that IC is an appropriate channel for the dissemination of institutional information, that can be used to plan the inclusion of cultural values.Com a eficiência da Comunicação Interna (CI) é possível que gestores consigam influenciar positivamente no comprometimento dos colaboradores com a instituição, internalizando as práticas desejadas, que passam a fazer parte das rotinas de trabalho. Ao planejar a CI os gestores devem inserir os valores culturais da organização, enviando aos colaboradores, de variadas formas, mensagens sobre o que a instituição espera deles. Com estas prerrogativas o presente trabalho objetivou identificar, na CI da Unioeste/Campus de Toledo, alguns vetores para transmissão dos valores culturais. Assim, esta pesquisa caracterizou-se como um estudo de caso, de natureza exploratória, utilizou-se da aplicação de questionários a todos os funcionários e ocupantes de cargos de chefia da Unioeste. Observou-se que há algumas falhas no processo de CI, as quais comprometem as ações e o alcance dos objetivos institucionais, e levam à falta de envolvimento e comprometimento dos atores envolvidos. Também verificou-se que os respondentes acreditam que a CI é um canal apropriado para a disseminação de informações institucionais, podendo ser utilizado para planejar a inserção de valores culturais

Evolution of clinical trials in ovarian cancer management over the past 20 years: never settle down, always go beyond

Purpose. A practice synthesis of available evidence-based medicine data in ovarian cancer (OC), aiming to provide directions for future research. Materials and Methods. We performed a systematic review. PubMed was searched for relevant OC trials between January 2000 and December 2019. Results. Out of 865 references screened, 199 trials were found eligible for inclusion. Most trials were multicenter (83.9%). There was a trend reduction in the number of patients enrolled/per study over the years. Studies testing targeted/biological therapies dominated the second decade (60 trials in 2010-2019 versus 2 trials in 2000-2009). The proportion of trials with positive survival and clinical outcomes significantly increased from 23.8% in early 2000s to 54.1% in the last 5 years. Trials with histology/molecular biomarker criteria were more likely to meet progression-free survival endpoint than those without these selection criteria (69.2% versus 32.6%). Conclusion. This systematic review suggests a trend of increased positive studies, mainly linked to precision medicine

First evidence of heteroplasmy in Grey Partridge (Perdix perdix)

Abstract We report for the first time the occurrence of heteroplasmy in Grey Partridge (Perdix perdix) revealed by means of two mitochondrial fragments. The possible serious biological and management implications of this exception to unilateral inheritance of mtDNA were underlined

Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850)

Objective To investigate the effect of treatment with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS), versus primary debulking surgery (PDS), on quality of life (QoL) in patients with advanced epithelial ovarian cancer (EOC).Design Randomised trial conducted in a single institution.Setting Division of Gynaecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.Sample Patients with stage-IIIC/IV EOC and high tumour load.Methods Patients were randomised (1:1) to undergo either PDS (PDS group) or NACT followed by IDS (NACT/IDS group).Main outcome measures Quality-of-life (QoL) data, assessed using the European Organization for Research and Treatment of Cancer core QoL questionnaire (QLQ-C30) and ovarian cancer module (OV28); co-primary outcomes were the QLQ-C30 global health score at 12 months (cross-sectional analysis) and the difference in mean QLQ-C30 global health score over time between treatment groups (longitudinal analysis).Results From October 2011 to May 2016, 171 patients were enrolled (PDS = 84; NACT/IDS = 87). We observed no clinical or statistically significant difference between treatment groups in any of the QoL functioning scales at 12 months, including QLQ-C30 global health score (NACT/IDS group vs PDS group, mean difference 4.7, 95% CI -4.99 to 14.4, p = 0.340). Over time, we found lower global health scores for those undergoing PDS than for those receiving NACT (difference in mean score 6.27, 95% CI 0.440-12.11, p = 0.035), albeit this was not clinically relevant.Conclusions We found no difference in global QoL related to treatment approach at 12 months, even though patients in the NACT/IDS group reported better global health scores across the 12-month period compared with the PDS group; these findings further confirm that NACT/IDS might be a feasible option for patients unsuitable for PDS

Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer

Introduction: In advanced epithelial ovarian cancer patients, the standard of care is primary debulking surgery, followed by first-line chemotherapy often with bevacizumab addiction. In this context, some experiences have shown that a comprehensive treatment approach to surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) could improve the prognosis. Objective: This is a study aimed to explore the feasibility of primary debulking surgery and HIPEC upfront followed by first-line therapy with bevacizumab. Study Design: Phase II monocentric, open label, non-randomised and single-arm study. Forty patients affected by advanced ovarian cancer submitted to primary debulking surgery with HIPEC were enrolled in the study. After surgery, all patients underwent systemic chemotherapy with bevacizumab addiction. Results: Complete cytoreduction (RT = 0) was achieved in all cases. Treatment-related early complications were observed in 23 patients and in 15 cases were G1–G2. Major complications were reported in 8 patients. No postoperative death was recorded. Subsequent chemotherapy was administered in all cases. Median time between surgery and first cycle of chemotherapy was 42 days (range 30–76). Concomitant bevacizumab was administered in 34 patients (85%). Maintenance with bevacizumab was feasible in 33 patients (82.5%) and its withdrawal was necessary for 1 patient (2.5%) due to G3 hypertension. Conclusion: Our data suggest that HIPEC can be safely introduced in the upfront therapy of advanced ovarian cancer